{"prompt": "['nephrectomy followed by surveillance imaging every 3 to 6 months for at least 3 years and then annually for up to 5 years.', 'Imaging', 'beyond 5 years should be performed as clinically indicated.', '7.1.4.1.4 RECIST 1.1', 'Objective response rate (ORR) is the primary endpoint for this study which will be evaluated. ORR will be based on the tumor', 'assessment performed by the investigators using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. This assessment will be', 'made based on the imaging obtained after the completion of 12 weeks of therapy but before nephrectomy as per', 'the', 'Trial', 'Flow', 'Chart.', 'Target lesions:', 'All tumor measurements will be recorded in centimeters. RECIST references a maximum of 5 lesions in total and 2 per organ that', 'should be identified as target lesions and recorded and measured at baseline. Non-lymph nodes must be at least 10mm', 'in', 'the', 'longest', 'diameter and lymph nodes must be at least 15mm in short axis to be included as a target lesion. Target lesions should be selected on', 'the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements (either by imaging', 'techniques or clinically). A sum of the longest diameter for all target lesions will be calculated and reported as the baseline sum', 'longest', 'diameter. The baseline sum of longest diameters will be used as the reference by which the objective tumor response is', 'characterized. Given that inclusion criteria for this study specifies that participants must have T3Nx or TanyN1 disease, it is likely that', 'only target lesion assessment will be required.', 'Non-target lesions:', 'All other lesions (or sites of disease) should also be recorded at baseline. There is no limit to the number of non-target lesions that can', 'be recorded at baseline. This may include lesions that are felt to represent neoplastic tissue but are difficult to measure in a', 'reproducible manner (e.g. bone metastases, leptomeningeal metastasis, ascites) although these are not expected as this is a trial of', 'locally advanced and not metastatic disease. Measurements of these lesions are not required, but the presence or absence of each', 'should be noted throughout follow-up.', 'New lesions:', 'Any lesion that was not recorded at baseline. There is no minimum size criteria to identify a new lesion and clinical judgment may be', 'used by the investigator. A new lesion should be unequivocal and not due to differences in scanning technique.', '47']['Target and non-target lesions will be evaluated after treatment as per Table 8.', 'Table 8. RECIST 1.1 evaluation of target and non-target lesions', 'Type of response', 'Definition', 'Complete response (CR)', 'Complete disappearance of all measurable and non-measurable lesions (from', 'baseline) and there are no unequivocal new lesions.', 'Lymph nodes must decrease to <10 mm in short axis.', 'Partial response (PR)', 'SOD post-treatment of target lesions (TLs) decreases by >30 % compared', 'to', 'SOD', 'baseline and there are no unequivocal new lesions, and no progression of', 'nontarget disease.', 'Stable disease (SD)', 'Failure to meet criteria for CR or PR in the absence of PD.', 'If the sum of the TLs and the status of the nontarget lesions do not reach the', 'criteria to meet PR or PD (increase >20% and at least 5 mm absolute increase in', 'SOD compared to baseline), the response is SD.', 'SD = neither 30% decrease compared to SOD', 'baseline', 'or 20% increase and at', 'least 5 mm absolute change compared to nadir.', 'Progressive disease (PD)', 'Minimum 20% increase and a minimum 5 mm absolute increase in SOD', 'compared to nadir, or PD for nontarget lesion(s) or unequivocal new lesion(s).', 'Not evaluable (NE)', 'Used in exceptional cases where insufficient data exists due to poor quality of', 'scans or missed scans or procedure', 'SODbaseline = Sum of diameters at baseline = longest diameter of all non-nodal + shortest diameter of all nodal target lesions', 'Best overall response after the completion of treatment will be evaluated as per Table 9.', 'Table 9. Evaluation of Best Overall Response per RECIST 1.1', 'Target Lesions (% change in', 'Non-Target Lesions Status', 'New Lesions Status', 'Overall Response (RECIST)', 'SOD)', '100', 'Absent', 'Absent', 'CR', '100', 'Present/NE', 'Absent', 'PR', '> 30', 'Present/Absent/NE', 'Absent', 'PR', '100', 'Present/Absent/NE', 'Present', 'PD', '> 30', '48']\n\n###\n\n", "completion": "END"}